Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page
- Check7 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the usual study content. Core study details and attached documents are no longer accessible from this page.SummaryDifference19%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe study record now shows an NIH funding annotation and the latest documentation version (v3.6.6) while the previous version tag (v3.6.5) is removed.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page’s revision label was updated from v3.6.4 to v3.6.5. This indicates a small, internal update to the page build without changing the study content.SummaryDifference0.0%

- Check56 days agoChange DetectedResults for the SatraGO-1 trial have been posted, and the study record now includes extensive outcome data such as Week 24/48 changes in proptosis, diplopia, CAS, GO-QoL, and safety events. The update also lists the associated documentation and timepoints for result reporting.SummaryDifference5%

- Check64 days agoChange DetectedThe page footer now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3. This indicates a minor site/software update.SummaryDifference0.0%

- Check78 days agoChange DetectedThe study's results status changed from 'No Results Posted' to 'Results Submitted', indicating that results have been submitted for the study and will be posted.SummaryDifference0.0%

Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.